Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers - Fig 1

<p><b>A. Identification and isolation of terpinen-4-ol.</b> Two mixtures (their composition is described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0156540#pone.0156540.t001" target="_blank">Table 1</a>) of monoterpens were tested on colorectal (HCT116, DLD1, COLO320), gastric (AGS), pancreatic (PANC-1, COLO357, MIA-PACA) and prostate (CL-1, DU145) cancer cell lines. 1x10⁴ cells were seeded in 96-well plates in complete medium. 0.05% of the mixtures were added to the cells on the next day. Cell survival was evaluated by enzymatic MTT assay72 h after the treatment. Each bar represents the mean±SD of a set of data determined in triplicates. *<i>P</i> < .<i>05</i>, **<i>P</i> < .<i>005</i>. <b>B. Terpinen-4-ol activity does not depend on the presence of DMSO.</b> 1x10⁴CRC, gastric, pancreatic and prostate cancer cells were seeded in 96-well plates in complete medium.0.05% of terpinen-4-ol with or without 0.01% DMSO was added to the cells on the next day. Cell survival was evaluated by enzymatic MTT assay72 h after the treatment. Each bar represents the mean±SD of a set of data determined in triplicates. *<i>P</i> < .<i>05</i>, **<i>P</i> < .<i>005</i>.